Greenwich LifeSciences, Inc. (GLSI)

NCM – Real vaqt narxi. Valyuta: USD

24.71

+0.58 (2.40%)

Yopilishda: May 12, 2026, 4:00 PM EDT

24.83

+0.12 (0.49%)

Bozor oldidan: May 13, 2026, 7:07 AM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Greenwich LifeSciences, Inc. (GLSI)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Greenwich LifeSciences, Inc. (GLSI)

Greenwich LifeSciences Provides Update Regarding Form 10-K Filing

Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026

Greenwich LifeSciences Provides Update on Financing Strategy

Greenwich LifeSciences: 'Buy' On Recent Open-Label Data And Patent Claim

Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential

Videolar

No Data

Press-relizlar

Greenwich LifeSciences Provides Update Regarding Form 10-K Filing

Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026

Search stocks

Greenwich LifeSciences, Inc. (GLSI)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Greenwich LifeSciences, Inc. (GLSI)

Greenwich LifeSciences Provides Update Regarding Form 10-K Filing

Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026

Greenwich LifeSciences Provides Update on Financing Strategy

Greenwich LifeSciences: 'Buy' On Recent Open-Label Data And Patent Claim

Greenwich LifeSciences Provides Update on Patent Claims Potentially Doubling GP2 Market Potential

Videolar

No Data

Press-relizlar

Greenwich LifeSciences Provides Update Regarding Form 10-K Filing

Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026